Benzinga
Benzinga
Noticias de España
Acciones
Índices
Bonos
ETFs
Economía
General
Noticias de EE.UU.
Acciones
Índices
Ganancias
Economía
Mercados de predicción
Mercados privados
Otros mercados
Calificaciones de analistas
Trading
Comunicados de prensa
Noticias Mundiales
Europa
Asia
Latinoamérica
Criptomonedas
Noticias
Altcoins
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Formación
Invertir en criptomonedas
Invertir en acciones
Forex
Benzinga
jueves, octubre 22
Noticias de España
Acciones
Índices
Bonos
ETFs
Economía
General
Noticias de EE.UU.
Acciones
Índices
Ganancias
Economía
Mercados de predicción
Mercados privados
Otros mercados
Calificaciones de analistas
Trading
Comunicados de prensa
Noticias Mundiales
Europa
Asia
Latinoamérica
Criptomonedas
Noticias
Altcoins
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Formación
Invertir en criptomonedas
Invertir en acciones
Forex
Acurx Pharmaceuticals Inc
ACXP
NASDAQ
Lista de seguimiento
Get Report
Trade with Public
Get Report
Trade with Public
$1.15
0.0027
0.23%
Últ. Act.: Oct 22, 12:25 PM
$1.14
-0.01
-0.87%
Get Report
Panorámica general
Noticias
Previsión de beneficios
Eventos
Precios objetivo
Finanzas
Sentimiento
Propiedad
Comparar
Informe de acciones
Privacy Manager
Acurx Pharmaceuticals Financials
Acurx Pharmaceuticals (ACXP) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
PRO
Acurx Pharmaceuticals Q2 EPS $(0.53) Misses $(0.37) Estimate
Acurx Pharmaceuticals (NASDAQ:ACXP) reported quarterly losses of $(0.53) per share which missed the analyst consensus estimate of $(0.37) by 43.24 percent. This is a 71.96 percent increase over losses of $(1.89) per
Benzinga Newsdesk
What's Going On With Acurx Pharmaceuticals Stock Today?
Acurx Pharmaceuticals (NASDAQ:ACXP) shares down on Friday after reporting net loss for Q4 2025, but with positive cash and $1.5M raised.
Nabaparna Bhattacharya
Earnings Scheduled For March 13, 2026
Benzinga Insights
PRO
Acurx Pharmaceuticals Q4 EPS $(0.73) Beats $(1.65) Estimate
Acurx Pharmaceuticals (NASDAQ:ACXP) reported quarterly losses of $(0.73) per share which beat the analyst consensus estimate of $(1.65) by 55.62 percent. This is a 78.53 percent increase over losses of $(3.40) per share
Benzinga Newsdesk
PRO
Acurx Pharmaceuticals Q3 EPS $(1.23) Beats $(1.31) Estimate
Acurx Pharmaceuticals (NASDAQ:ACXP) reported quarterly losses of $(1.23) per share which beat the analyst consensus estimate of $(1.31) by 6.11 percent. This is a 64.35 percent increase over losses of $(3.45) per share
Benzinga Newsdesk
Earnings Scheduled For November 12, 2025
Benzinga Insights
